Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 156

1.

Only monospecific anti-DFS70 antibodies aid in the exclusion of antinuclear antibody associated rheumatic diseases: an Italian experience.

Infantino M, Pregnolato F, Bentow C, Mahler M, Benucci M, Li Gobbi F, Damiani A, Grossi V, Franceschini F, Bodio C, Borghi MO, Manfredi M.

Clin Chem Lab Med. 2019 Jul 18. pii: /j/cclm.ahead-of-print/cclm-2019-0454/cclm-2019-0454.xml. doi: 10.1515/cclm-2019-0454. [Epub ahead of print]

PMID:
31318689
2.

The Laboratory Role in anti-TNF Biological Therapy Era.

Grossi V, Gulli F, Infantino M, Stefanile A, Napodano C, Benucci M, Pocino K, Li Gobbi F, Damiani A, Di Pino A, Manfredi M, Marino M, Basile V, Rapaccini GL, Basile U.

Immunol Invest. 2019 Jul 12:1-16. doi: 10.1080/08820139.2019.1637434. [Epub ahead of print]

PMID:
31298595
3.

Abatacept: from a budget impact model to cost-effectiveness analysis - data from RCT and real life.

Benucci M, Damiani A, Manfredi M, Infantino M, Grossi V, Li Gobbi F.

Clinicoecon Outcomes Res. 2019 Jun 7;11:405-409. doi: 10.2147/CEOR.S192910. eCollection 2019.

4.

Increased prevalence of anti-DFS70 antibodies in young females: experience from a large international multi-center study on blood donors.

Albesa R, Sachs U, Infantino M, Manfredi M, Benucci M, Baus Y, Lutterbeck S, Andrade L, Morris K, Friedenberg A, Casas S, Bossuyt X, Mahler M.

Clin Chem Lab Med. 2019 Jun 26;57(7):999-1005. doi: 10.1515/cclm-2018-1233.

PMID:
30739097
5.

Combining immunofluorescence with immunoblot assay improves the specificity of autoantibody testing for myositis.

Infantino M, Tampoia M, Fabris M, Alessio MG, Previtali G, Pesce G, Deleonardi G, Porcelli B, Musso M, Grossi V, Benucci M, Manfredi M, Bizzaro N.

Rheumatology (Oxford). 2019 Jul 1;58(7):1239-1244. doi: 10.1093/rheumatology/key451.

PMID:
30726990
6.

Improved accuracy in DFS pattern interpretation using a novel HEp-2 ELITE system.

Infantino M, Shovman O, Gilburd B, Manfredi M, Grossi V, Benucci M, Damiani A, Chimenti D, Malyavantham K, Shoenfeld Y.

Clin Rheumatol. 2019 May;38(5):1293-1299. doi: 10.1007/s10067-018-04412-1. Epub 2019 Jan 7.

PMID:
30617598
7.

Concomitant Spondyloarthritis and Tenosynovial Giant Cell Tumor in Pigmented Villonodular Synovitis Challenging Cases.

Manetti M, Mondanelli N, Rosa I, Ibba-Manneschi L, Benucci M, Bandinelli F.

J Clin Rheumatol. 2018 Dec 28. doi: 10.1097/RHU.0000000000000985. [Epub ahead of print] No abstract available.

PMID:
30601200
8.

Personalization of biologic therapy in patients with rheumatoid arthritis: less frequently accounted choice-driving variables.

Niccoli L, Nannini C, Blandizzi C, Mantarro S, Mosca M, Di Munno O, Goletti D, Benucci M, Gobbi FL, Cassarà E, Kaloudi O, Cantini F.

Ther Clin Risk Manag. 2018 Oct 24;14:2097-2111. doi: 10.2147/TCRM.S175772. eCollection 2018.

9.

Mandatory, cost-driven switching from originator etanercept to its biosimilar SB4: possible fallout on non-medical switching.

Cantini F, Benucci M.

Ann Rheum Dis. 2018 Nov 28. pii: annrheumdis-2018-214757. doi: 10.1136/annrheumdis-2018-214757. [Epub ahead of print] No abstract available.

PMID:
30487149
10.

Switch or swap strategy in rheumatoid arthritis patients failing TNF inhibitors? Results of a modified Italian Expert Consensus.

Todoerti M, Favalli EG, Iannone F, Olivieri I, Benucci M, Cauli A, Mathieu A, Santo L, Minisola G, Lapadula G, Bucci R, Gremese E, Caporali R.

Rheumatology (Oxford). 2018 Oct 1;57(57 Suppl 7):vii42-vii53. doi: 10.1093/rheumatology/key195. Review.

PMID:
30289539
11.

Focus on biosimilar etanercept - bioequivalence and interchangeability.

Cantini F, Benucci M.

Biologics. 2018 Aug 30;12:87-95. doi: 10.2147/BTT.S126854. eCollection 2018. Review.

12.

Tocilizumab modulates serum levels of adiponectin and chemerin in patients with rheumatoid arthritis: potential cardiovascular protective role of IL-6 inhibition.

Fioravanti A, Tenti S, Bacarelli MR, Damiani A, Li Gobbi F, Bandinelli F, Cheleschi S, Galeazzi M, Benucci M.

Clin Exp Rheumatol. 2019 Mar-Apr;37(2):293-300. Epub 2018 Aug 27.

13.

Letter to the Editor relating to Clin Chem Lab Med 2018;56(7):1090-1099.

Infantino M, Grossi V, Benucci M, Manfredi M.

Clin Chem Lab Med. 2019 Mar 26;57(4):e45-e46. doi: 10.1515/cclm-2018-0599. No abstract available.

PMID:
30138111
14.

A better definition of the anti-DFS70 antibody screening by IIF methods.

Infantino M, Shovman O, Pérez D, Grossi V, Manfredi M, Benucci M, Damiani A, Gilburd B, Azoulay D, Serrano A, Shoenfeld Y.

J Immunol Methods. 2018 Oct;461:110-116. doi: 10.1016/j.jim.2018.07.001. Epub 2018 Jul 11.

PMID:
30017652
15.

Autoantibody profile and clinical patterns in 619 Italian patients with cutaneous lupus erythematosus.

Verdelli A, Coi A, Marzano AV, Antiga E, Cozzani E, Quaglino P, La Placa M, Benucci M, De Simone C, Papini M, Parodi A, Bianchi F, Caproni M.

J Eur Acad Dermatol Venereol. 2019 Apr;33(4):742-752. doi: 10.1111/jdv.15147. Epub 2018 Jul 12.

PMID:
29924416
16.

Factors correlated with the improvement of endothelial dysfunction during Abatacept therapy in patients with rheumatoid arthritis.

Benucci M, Bandinelli F, Damiani A, Gobbi FL, Infantino M, Grossi V, Manfredi M.

J Inflamm Res. 2018 Jun 7;11:247-252. doi: 10.2147/JIR.S156822. eCollection 2018.

17.

Analytical variability in the determination of anti-double-stranded DNA antibodies: the strong need of a better definition of the old and new tests.

Infantino M, Manfredi M, Merone M, Grossi V, Benucci M, Li Gobbi F, Bandinelli F, Damiani A, Soda P.

Immunol Res. 2018 Jun;66(3):340-347. doi: 10.1007/s12026-018-8992-9.

PMID:
29623613
18.

Anti-DFS70 autoantibodies in undifferentiated connective tissue diseases subjects: what's on the horizon?

Infantino M, Shovman O, Pérez D, Manfredi M, Grossi V, Benucci M, Gobbi FL, Bandinelli F, Damiani A, Moscato P, Azoulay D, Gilburd B, Shoenfeld Y.

Rheumatology (Oxford). 2018 Apr 3. doi: 10.1093/rheumatology/key012. [Epub ahead of print]

PMID:
29618128
19.

Detection of myositis-specific antibodies: additional notes.

Infantino M, Manfredi M, Grossi V, Benucci M.

Ann Rheum Dis. 2019 Apr;78(4):e29. doi: 10.1136/annrheumdis-2018-213320. Epub 2018 Mar 13. No abstract available.

PMID:
29535123
20.

Ankylosing Spondylitis Treatment after First Anti-TNF Drug Failure.

Benucci M, Damiani A, Bandinelli F, Grossi V, Infantino M, Manfredi M, Gobbi FL, Sarzi-Puttini P, Atzeni F.

Isr Med Assoc J. 2018 Feb;20(2):119-122. Review. No abstract available.

21.

Correlation between HLA haplotypes and the development of antidrug antibodies in a cohort of patients with rheumatic diseases.

Benucci M, Damiani A, Li Gobbi F, Bandinelli F, Infantino M, Grossi V, Manfredi M, Noguier G, Meacci F.

Biologics. 2018 Jan 31;12:37-41. doi: 10.2147/BTT.S145941. eCollection 2018.

22.

Additional comment to: 'Switching from the bio-originators to biosimilar: is it premature to recommend this procedure?' by Scherlinger and Schaeverbeke.

Cantini F, Benucci M.

Ann Rheum Dis. 2019 Apr;78(4):e25. doi: 10.1136/annrheumdis-2018-213044. Epub 2018 Feb 2. No abstract available.

PMID:
29420201
23.

Tocilizumab after a first-line with anti-TNF in rheumatoid arthritis: a cost-consequence analysis in the Italian setting.

Iannazzo S, Benucci M, Favalli EG.

Clin Exp Rheumatol. 2018 May-Jun;36(3):479-485. Epub 2018 Jan 15.

PMID:
29352843
24.

The role of klotho in systemic sclerosis.

Talotta R, Bongiovanni S, Letizia T, Rigamonti F, Atzeni F, Benucci M, Vago T, Sarzi-Puttini P.

Reumatismo. 2017 Dec 21;69(4):156-163. doi: 10.4081/reumatismo.2017.987.

25.

Switching from the bio-originators to biosimilar: is it premature to recommend this procedure?

Cantini F, Benucci M.

Ann Rheum Dis. 2019 Apr;78(4):e23. doi: 10.1136/annrheumdis-2017-212820. Epub 2017 Dec 29. No abstract available.

PMID:
29288210
26.

Interstitial lung disease in systemic autoimmune rheumatic diseases: a comprehensive review.

Atzeni F, Gerardi MC, Barilaro G, Masala IF, Benucci M, Sarzi-Puttini P.

Expert Rev Clin Immunol. 2018 Jan;14(1):69-82. doi: 10.1080/1744666X.2018.1411190. Epub 2017 Dec 11. Review.

PMID:
29202589
27.

Reflex testing of speckled cytoplasmic patterns observed in routine ANA HEp-2 indirect immunofluorescence with a multiplex anti-synthetase dot-blot assay: a multicentric pilot study.

Infantino M, Palterer B, Biagiotti R, Almerigogna F, Benucci M, Damiani A, Grossi V, Azzurri A, Casprini P, Bacci G, Giudizi MG, Manfredi M.

Immunol Res. 2018 Feb;66(1):74-78. doi: 10.1007/s12026-017-8974-3.

PMID:
29159696
28.

An effective algorithm for the serological diagnosis of idiopathic inflammatory myopathies: The key role of anti-Ro52 antibodies.

Infantino M, Manfredi M, Grossi V, Benucci M, Morozzi G, Tonutti E, Tampoia M, Bizzaro N.

Clin Chim Acta. 2017 Dec;475:15-19. doi: 10.1016/j.cca.2017.10.002. Epub 2017 Oct 3.

PMID:
28986052
29.

Measurement of Serum Klotho in Systemic Sclerosis.

Talotta R, Bongiovanni S, Letizia T, Rigamonti F, Ditto MC, Atzeni F, Salaffi F, Batticciotto A, Gerardi MC, Antivalle M, Vago T, Benucci M, Sarzi-Puttini P.

Dis Markers. 2017;2017:9545930. doi: 10.1155/2017/9545930. Epub 2017 Aug 22.

30.

Jaccoud's arthropathy, an unusual manifestation of idiopathic retroperitoneal fibrosis: rapid improvement of symptoms after tocilizumab treatment.

Benucci M, Damiani A, Li Gobbi F, Grossi V, Infantino M, Arena A, Manfredi M.

Reumatismo. 2017 Aug 3;69(2):88-91. doi: 10.4081/reumatismo.2017.968.

31.

Timing of onset affects arthritis presentation pattern in antisyntethase syndrome.

González-Gay MA, Montecucco C, Selva-O'Callaghan A, Trallero-Araguas E, Molberg O, Andersson H, Rojas-Serrano J, Perez-Roman DI, Bauhammer J, Fiehn C, Neri R, Barsotti S, Lorenz HM, Doria A, Ghirardello A, Iannone F, Giannini M, Franceschini F, Cavazzana I, Triantafyllias K, Benucci M, Infantino M, Manfredi M, Conti F, Schwarting A, Sebastiani G, Iuliano A, Emmi G, Silvestri E, Govoni M, Scirè CA, Furini F, Lopez-Longo FJ, Martínez-Barrio J, Sebastiani M, Manfredi A, Bachiller-Corral J, Sifuentes Giraldo WA, Cimmino MA, Cosso C, Belotti Masserini A, Cagnotto G, Codullo V, Romano M, Paolazzi G, Pellerito R, Saketkoo LA, Ortego-Centeno N, Quartuccio L, Batticciotto A, Bartoloni Bocci E, Gerli R, Specker C, Bravi E, Selmi C, Parisi S, Salaffi F, Meloni F, Marchioni E, Pesci A, Dei G, Confalonieri M, Tomietto P, Nuno L, Bonella F, Pipitone N, Mera-Valera A, Perez-Gomez N, Gerzeli S, Lopez-Mejias R, Matos-Costa CJ, Pereira da Silva JA, Cifrian J, Alpini C, Olivieri I, Blázquez Cañamero MÁ, Rodriguez Cambrón AB, Castañeda S, Cavagna L; AENEAS (American and European NEtwork of Antisynthetase Syndrome) collaborative group.

Clin Exp Rheumatol. 2018 Jan-Feb;36(1):44-49. Epub 2017 Jul 26.

32.
33.

The impact of biological treatments on the anti-dsDNA and anti-nucleosome tests.

Infantino M, Grossi V, Benucci M, Li Gobbi F, Damiani A, Manfredi M.

Lupus. 2018 Jan;27(1):40-48. doi: 10.1177/0961203317709344. Epub 2017 Jun 6.

PMID:
28587585
34.

Second-line biologic therapy optimization in rheumatoid arthritis, psoriatic arthritis, and ankylosing spondylitis.

Cantini F, Niccoli L, Nannini C, Cassarà E, Kaloudi O, Giulio Favalli E, Becciolini A, Benucci M, Gobbi FL, Guiducci S, Foti R, Mosca M, Goletti D.

Semin Arthritis Rheum. 2017 Oct;47(2):183-192. doi: 10.1016/j.semarthrit.2017.03.008. Epub 2017 Mar 22. Review.

PMID:
28413099
35.

Comparison of methods and TAT assessment: Volumetric AQUIOS CL and bead-based FACS CANTO II cytometers.

Grossi V, Infantino M, Meacci F, Bellio E, Bellio V, Ciotta G, Priami F, Sarzi-Puttini P, Atzeni F, Li Gobbi F, Damiani A, Benucci M, Manfredi M.

Cytometry B Clin Cytom. 2018 Jul;94(4):674-678. doi: 10.1002/cyto.b.21513. Epub 2017 Feb 15.

36.

Biological Agents in Rheumatoid Arthritis: A Cross-Link Between Immune Tolerance and Immune Surveillance.

Talotta R, Atzeni F, Batticciotto A, Benucci M, Bongiovanni S, Sarzi-Puttini P.

Curr Rheumatol Rev. 2018;14(2):131-139. doi: 10.2174/1573397112666161230125317. Review.

PMID:
28034349
37.

Aseptic HLA B27-positive spondylodiscitis: decreased 18F-FDG uptake after etanercept treatment.

Benucci M, Damiani A, Arena A, Infantino M, Manfredi M, Li Gobbi F.

Reumatismo. 2016 Dec 16;68(3):163-165. doi: 10.4081/reumatismo.2016.911.

38.

What are the dangers of biological therapy discontinuation or dose reduction strategies when treating rheumatoid arthritis?

Atzeni F, Benucci M, Talotta R, Masala IF, Sarzi-Puttini P, Govoni M.

Expert Rev Clin Pharmacol. 2016 Nov;9(11):1403-1411. doi: 10.1080/17512433.2016.1234374. Epub 2016 Oct 20. Review.

PMID:
27634311
39.

The burden of the variability introduced by the HEp-2 assay kit and the CAD system in ANA indirect immunofluorescence test.

Infantino M, Meacci F, Grossi V, Manfredi M, Benucci M, Merone M, Soda P.

Immunol Res. 2017 Feb;65(1):345-354. doi: 10.1007/s12026-016-8845-3.

PMID:
27456204
40.

Safety, efficacy and immunogenicity of switching from innovator to biosimilar infliximab in patients with spondyloarthritis: a 6-month real-life observational study.

Benucci M, Gobbi FL, Bandinelli F, Damiani A, Infantino M, Grossi V, Manfredi M, Parisi S, Fusaro E, Batticciotto A, Sarzi-Puttini P, Atzeni F, Meacci F.

Immunol Res. 2017 Feb;65(1):419-422. doi: 10.1007/s12026-016-8843-5.

PMID:
27449503
41.

The clinical impact of Anti-DFS70 antibodies in undifferentiated connective tissue disease: case reports and a review of the literature.

Infantino M, Meacci F, Grossi V, Manfredi M, Li Gobbi F, Sarzi-Puttini P, Atzeni F, Benucci M.

Immunol Res. 2017 Feb;65(1):293-295. doi: 10.1007/s12026-016-8836-4. Review.

PMID:
27427300
42.

Infliximab and CT-P13 immunogenicity assessment in PLANETAS and PLANETRAS main and extension studies: utility of laboratory methods description.

Meacci F, Manfredi M, Infantino M, Grossi V, Benucci M.

Ann Rheum Dis. 2016 Oct;75(10):e62. doi: 10.1136/annrheumdis-2016-210078. Epub 2016 Jul 11. No abstract available.

PMID:
27401744
43.

A Proposed Serum Calprotectin IgG Cut-Off Level for Diagnosing Inflammatory Arthritis.

Grossi V, Infantino M, Manfredi M, Meacci F, Bellio E, Bellio V, Gobbi FL, Ugolini S, Catani S, Sarzi-Puttini P, Atzeni F, Benucci M.

Curr Rheumatol Rev. 2017;13(2):93-97. doi: 10.2174/1573397112666160629085231.

PMID:
27363504
44.

Infections and Biological Therapy in Patients with Rheumatic Diseases.

Atzeni F, Batticciotto A, Masala IF, Talotta R, Benucci M, Sarzi-Puttini P.

Isr Med Assoc J. 2016 Mar-Apr;18(3-4):164-7. Review.

45.

Anti Etanercept and anti SB4 antibodies detection: impact of the assay method.

Meacci F, Manfredi M, Infantino M, Grossi V, Benucci M.

Ann Rheum Dis. 2016 Jul;75(7):e39. doi: 10.1136/annrheumdis-2016-209665. Epub 2016 Apr 29. No abstract available.

PMID:
27130906
46.

Correlations between immunogenicity, drug levels, and disease activity in an Italian cohort of rheumatoid arthritis patients treated with tocilizumab.

Benucci M, Meacci F, Grossi V, Infantino M, Manfredi M, Bellio E, Bellio V, Li Gobbi F, Bazzichi L, Moscato P, Caputo D, Saviola G, Talotta R, Sarzi-Puttini P, Atzeni F.

Biologics. 2016 Mar 11;10:53-8. doi: 10.2147/BTT.S97234. eCollection 2016.

47.

SERUM CALPROTECTIN LEVELS AS A MARKER OF ARTHRITIS: AN ITALIAN EXPERIENCE.

Grossi V, Infantino M, Manfredi M, Meacci F, Bellio E, Bellio V, Gobbi FL, Ugolini S, Catani S, Sarzi-Puttini P, Atzeni F, Benucci M.

Curr Rheumatol Rev. 2016 Mar 31. [Epub ahead of print]

PMID:
27030256
48.

Anti-peptidyl-arginine deaminase 3 (PAD3) antibodies as a promising marker to measure joint damage in patients with rheumatoid arthritis.

Seaman A, Darrah E, Infantino M, Meacci F, Manfredi M, Benucci M, Mahler M.

Autoimmun Rev. 2016 Jul;15(7):776-80. doi: 10.1016/j.autrev.2016.03.016. Epub 2016 Mar 18. Review.

PMID:
26997641
49.

Costs associated with rheumatoid arthritis in Italy: past, present, and future.

Benucci M, Rogai V, Atzeni F, Hammen V, Sarzti-Puttini P, Migliore A.

Clinicoecon Outcomes Res. 2016 Feb 10;8:33-41. doi: 10.2147/CEOR.S91006. eCollection 2016. Review.

50.

Serological epitope profile of anti-Ro52-positive patients with systemic autoimmune rheumatic diseases.

Infantino M, Meacci F, Grossi V, Benucci M, Morozzi G, Tonutti E, Tampoia M, Ott A, Meyer W, Atzeni F, Sarzi-Puttini P, Manfredi M, Bizzaro N.

Arthritis Res Ther. 2015 Dec 17;17:365. doi: 10.1186/s13075-015-0871-3.

Supplemental Content

Loading ...
Support Center